Valtropin News
Most Popular Valtropin Story
ALSO NOTED: Oragenics trial on hold; Epix gains $3M milestone; More bad new for Novartis; and much more...
> An early-stage safety trial of a cavity-prevention therapy from Oragenics has been placed on hold by U.S. regulators. Read more...
Latest Headlines
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
